Cardio-Oncology
Submission Deadline: 15 Mar 2022
Guest Editors
Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan;School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan;Graduate Institute of Medicine, Yuan Ze University, Taoyuan, Taiwan
Interests: cardiology; heart failure; atherosclerosis; biomarkers; nuclear medicine; SPECT; PET; molecular imaging
Special Issue in IMR Press journals
Special Issue in Management of Cardiac Amyloidosis
Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; National Taiwan University College of Medicine, Taipei,Taiwan
Interests: Cardiovascular epidemiology; Hypertension; Cardio-oncology
Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University; Institute of Clinical Medicine, College of Medicine, National Cheng Kung University
Interests: Stem cell research; Cardiac regeneration; Echocardiography; Cancer therapy related cardiac dysfunction; Cardio-oncology
Division of Radiation Oncology, Department of Radiology, Far Eastern Memorial Hospital, New Taipei City, Taiwan, National Yang Ming Chiao Tung University, School of Medicine, Faculty of Medicine, Taipei, Taiwan
Interests: Stereotactic Body Radiation Therapy (SBRT); Image-Guided Radiotherapy (IGRT); Radiation related cardiotoxicity; Radiation related pneumonitis
Special Issue Information
Dear Colleagues,
The two top causes of death in the world are cancer and cardiovascular disease, and cardiovascular demands to the care of cancer patients are common and important given the implications for morbidity and mortality. Cancer treatment has advanced rapidly from surgery, cytotoxic chemotherapy, radiation therapy, and targeted and immune-based therapies over the past decades. These advances have led to an increase in the number of cancer survivors, however an emerging issue associated with these new cancer therapies is side effects on the cardiovascular system, which cause different spectrums of morbidity and mortality. In order to explor and detect cancer therapeutics–related cardiovascular dysfunction and mitigate its progression, the both fields are closely intertwined with each other.
This Special Issue takes specific focus on the current state of cardio-oncology field and especially cancer therapy-related cardiac dysfunction—exploring the mechnisms, reviewing the current status including dignoastic and imaging modalites, team-based care and personalised approaches, and clinical unmet needs, with recommendations to minimise the risk of cardiovascular toxicity from cancer therapies and the development of dedicated cardio-oncology care.
Dr. Yen-Wen Wu, Dr. Hung-Ju Lin, Dr. Yen-Wen Liu and Dr. Pei-Wei Shueng
Guest Editors
Keywords
- Cadio-oncology
- Cancer therapy-related cardiac dysfunction
- Cardiotoxicity
- Heart failure
- Imaging
- Biomarkers
- Diagnostic and prognostic application
Published Papers (3)
Left Ventricular-Arterial Coupling and Vascular Function in Childhood Cancer Survivors Exposed to Anthracycline Chemotherapy
Rev. Cardiovasc. Med. 2023, 24(4), 124; https://doi.org/10.31083/j.rcm2404124
(This article belongs to the Special Issue Cardio-Oncology)
Application of Carotid Duplex Ultrasonography in the Surveillance of Carotid Artery Stenosis after Neck Irradiation
Rev. Cardiovasc. Med. 2022, 23(7), 240; https://doi.org/10.31083/j.rcm2307240
(This article belongs to the Special Issue Cardio-Oncology)
Mechanisms of Myocardial Ischemia in Cancer Patients: A State-of-the-Art Review of Obstructive Versus Non-Obstructive Causes
Rev. Cardiovasc. Med. 2022, 23(7), 227; https://doi.org/10.31083/j.rcm2307227
(This article belongs to the Special Issue Cardio-Oncology)